<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">AIDS</journal-id><journal-id journal-id-type="iso-abbrev">AIDS</journal-id><journal-id journal-id-type="publisher-id">AIDS</journal-id><journal-title-group><journal-title>AIDS (London, England)</journal-title></journal-title-group><issn pub-type="ppub">0269-9370</issn><issn pub-type="epub">1473-5571</issn><publisher><publisher-name>Lippincott Williams &#x00026; Wilkins</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6903426</article-id><article-id pub-id-type="publisher-id">AIDS-D-19-00647</article-id><article-id pub-id-type="doi">10.1097/QAD.0000000000002382</article-id><article-id pub-id-type="art-access-id">00019</article-id><article-categories><subj-group subj-group-type="heading"><subject>Correspondence</subject></subj-group></article-categories><title-group><article-title>HIV viral load algorithm: what are the needs in the field?</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Breton</surname><given-names>Guillaume</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Laborde-Balen</surname><given-names>Gabri&#x000e8;le</given-names></name><xref ref-type="aff" rid="aff2"><sup>b</sup></xref><xref ref-type="aff" rid="aff3"><sup>c</sup></xref></contrib><contrib contrib-type="author"><name><surname>Guilavogui</surname><given-names>Foromo</given-names></name><xref ref-type="aff" rid="aff4"><sup>d</sup></xref></contrib><contrib contrib-type="author"><name><surname>Karemangino</surname><given-names>Saidi</given-names></name><xref ref-type="aff" rid="aff5"><sup>e</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zana</surname><given-names>Daniel K.</given-names></name><xref ref-type="aff" rid="aff6"><sup>f</sup></xref></contrib><contrib contrib-type="author"><name><surname>Temgoua</surname><given-names>Edith M.</given-names></name><xref ref-type="aff" rid="aff7"><sup>g</sup></xref></contrib><contrib contrib-type="author"><name><surname>Rouzioux</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="aff8"><sup>h</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pizarro</surname><given-names>Louis</given-names></name><xref ref-type="aff" rid="aff1"><sup>a</sup></xref></contrib><contrib contrib-type="author"><name><surname>Tubiana</surname><given-names>Roland</given-names></name><xref ref-type="aff" rid="aff9"><sup>i</sup></xref></contrib></contrib-group><contrib-group><contrib contrib-type="collab"><collab>the &#x02018;let's talk about failure&#x02019; working group</collab></contrib></contrib-group><aff id="aff1"><label>a</label>Solthis, Bagnolet</aff><aff id="aff2"><label>b</label>IRD UMI 233 TransVIHMI-INSERM U1175, Montpellier University, Montpellier, France</aff><aff id="aff3"><label>c</label>Centre r&#x000e9;gional de Recherche et de formation &#x000e0; la prise en charge Clinique de Fann, Dakar, Senegal</aff><aff id="aff4"><label>d</label>PNLSH, Conakry, Guinea</aff><aff id="aff5"><label>e</label>PNLS/IST, Bujumbura, Burundi</aff><aff id="aff6"><label>f</label>PNLS, Abidjan, C&#x000f4;te d&#x02019;Ivoire</aff><aff id="aff7"><label>g</label>CNLS, Yaound&#x000e9;, Cameroun</aff><aff id="aff8"><label>h</label>Department of Virology, Necker Hospital</aff><aff id="aff9"><label>i</label>Department of Infectious and Tropical Diseases, Piti&#x000e9;-Salp&#x000ea;tri&#x000e8;re Hospital, Paris, France.</aff><author-notes><corresp>Correspondence to Guillaume Breton, Solthis, Bagnolet, France. E-mail: <email>guillaume.breton@solthis.org</email></corresp></author-notes><pub-date pub-type="ppub"><day>1</day><month>1</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>05</day><month>11</month><year>2019</year></pub-date><volume>34</volume><issue>1</issue><fpage>159</fpage><lpage>160</lpage><history><date date-type="received"><day>05</day><month>8</month><year>2019</year></date><date date-type="accepted"><day>30</day><month>8</month><year>2019</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2019 The Author(s). Published by Wolters Kluwer Health, Inc.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0">http://creativecommons.org/licenses/by-nc-nd/4.0</ext-link></license-p></license></permissions><self-uri xlink:type="simple" xlink:href="aids-34-159.pdf"/><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>We have read with interest the study published by Shoufri <italic>et al.</italic>[<xref rid="R1" ref-type="bibr">1</xref>] and share the idea that the current application of the WHO viral load algorithm does not allow for effective management of patients with virological failure, whereas the emergence of HIV drug resistance, so-called the fourth HIV epidemic, is obvious [<xref rid="R2" ref-type="bibr">2</xref>].</p><p>We would like to provide some comments based on our experience in implementing viral load in the framework of the OPP-ERA project, which implements an open viral load platform technique in West and Central Africa (WCA).</p><p>First, we regret that data from WCA have not been included, as too often in research, when this region represents a quarter of people living with HIV in sub-Saharan Africa, which makes these conclusions less generalizable at the sub-Saharan African level. In WCA, primary non-nucleoside reverse transcriptase inhibitors resistance data are currently lower than in East and Southern Africa [<xref rid="R3" ref-type="bibr">3</xref>]. In the framework of the OPP-ERA project, adherence strengthening targeting more than 9000 patients with viral load at least 1000 copies/ml in Guinea and Burundi made it possible to obtain a viral load less than 1000 copies/ml in 50% of cases, avoiding unjustified use of second line (personal data).</p><p>Second, even if a simplified algorithm could be applied for efavirenz-based treatment, this strategy is unlikely to be adapted to the higher genetic barrier of the dolutegravir, used as first-line regimen, for which adherence strengthening is more likely to be effective, as shown with boosted protease inhibitors-based second-line strategies [<xref rid="R4" ref-type="bibr">4</xref>]. As suggested, drug regimen-specific failure algorithm may be an option; however, it seems complex to implement, as evidenced by the difficulties faced in using the current algorithm, despite its apparent simplicity.</p><p>Indeed, the use of the current viral load algorithm in case of failure is very low: in the OPP-ERA project, less than 15% of patients with viral load at least 1000 copies/ml benefited from a viral load control within 3&#x02013;6 (or 9) months and second-line switch is anecdotal (personal data), as shown in previous study [<xref rid="R5" ref-type="bibr">5</xref>]. These problems should be explored before any new recommendations.</p><p>We have conducted qualitative surveys, which allows formulation of hypotheses.</p><p>From HIV programmes&#x02019; point of view, the decrease in international funding pushes programmes to make difficult choices: should we favour the purchase of first-line drugs to treat all new patients in a test and treat perspective or rather second-line drugs, knowing that second-line drugs cost about two to five times more than first-line drugs?</p><p>A minimal use of the second-line seems thus to have been promoted by adapting the WHO algorithm: in case of viral load at least 1000 copies/ml, &#x02018;evaluate for adherence concern&#x02019; has been changed into &#x02018;adherence strengthening&#x02019;.</p><p>From the prescribers&#x02019; point of view, ensuring that adherence has been sufficiently strengthened seems a major concern in the absence of an objective measure of adherence and this especially since patients in virological failure suffer from negative representation such as &#x02018;liars&#x02019; or &#x02018;delinquent&#x02019;. Viral load seems often considered as a measure of nonadherence, which should therefore be sufficiently strengthened before proposing second line. Moreover, even if the viral load algorithm is well known, its interpretation is difficult: the 1000 copies/ml threshold is poorly respected in practice. Even a modest decrease in viral load after adherence strengthening is considered as a success, which often leads to further adherence interventions to &#x02018;give a chance to the first line&#x02019; to reach a viral load less than 1000 copies/ml, leading to repeated adherence interventions and viral load control with very low and delayed switch to second line, with deleterious effects to the patients and to the epidemic.</p><p>In addition, prescribers and patients are not prepared for failure, the announcement is most often dramatic and guilt-ridden, the mechanisms of failure are poorly analysed and patients are not prepared for second line, generating the subsequent risk of failure, even more dramatic because of the very low availability of the third line [<xref rid="R6" ref-type="bibr">6</xref>]. To overcome this issue, we have set up the &#x02018;let's talk about failure&#x02019; working group, which is currently working on a practical guideline.</p><p>It is therefore necessary to keep in mind the need to accompany the current algorithm and any potential modifications with a practical translation corresponding to the realities in the field. Above all, future algorithms should be designed as to be integrated into the reality of the countries&#x02019; health system and its various components, particularly in terms of finance, procurement, health information system, lab and clinical human resources capacity building, so that efforts to increase access to viral load can lead to improving patient care and not just informing the third 90%.</p><sec><title>Acknowledgements</title><sec><title>Conflicts of interest</title><p>Response to Shoufri A, <italic>et al.</italic> AIDS 2019;33:1635&#x02013;44.</p><p><italic>&#x02018;Let's talk about failure&#x02019; working group:</italic> AMAN C.M.L. (Abidjan), BRETON G. (Bagnolet), DOUOLI S.M. (Abidjan), GAKIMA D. (Bujumbura), GOUESSE Y.P. (Abidjan), GUILAVOGUI F. (Conakry), KAREMANGINO S. (Bujumbura), KAREMERA F. (Bujumbura), MAMANE H. (Conakry), MOUKOKO DOUALLA A.C.M. (Cameroun), SOUMAH M.M. (Conakry), TEMGOUA E.M. (Yound&#x000e9;), ZANA D.K. (Abidjan).</p></sec></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shoufri</surname><given-names>A</given-names></name><name><surname>Van Cutsem</surname><given-names>G</given-names></name><name><surname>Cambiano</surname><given-names>V</given-names></name><name><surname>Bansi-Matharu</surname><given-names>L</given-names></name><name><surname>Duncan</surname><given-names>K</given-names></name><name><surname>Murphy</surname><given-names>RA</given-names></name><etal/></person-group>
<article-title>Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure</article-title>. <source><italic>AIDS</italic></source>
<year>2019</year>; <volume>33</volume>:<fpage>1635</fpage>&#x02013;<lpage>1644</lpage>.<pub-id pub-id-type="pmid">31305331</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laborde-Balen</surname><given-names>G</given-names></name><name><surname>Taverne</surname><given-names>B</given-names></name><name><surname>Ndour</surname><given-names>CT</given-names></name><name><surname>Kouanfack</surname><given-names>C</given-names></name><name><surname>Peeters</surname><given-names>M</given-names></name><name><surname>Ndoye</surname><given-names>I</given-names></name><name><surname>Delaporte</surname><given-names>E</given-names></name></person-group>
<article-title>The fourth HIV epidemic</article-title>. <source><italic>Lancet Infect Dis</italic></source>
<year>2018</year>; <volume>18</volume>:<fpage>379</fpage>&#x02013;<lpage>380</lpage>.</mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="book"><comment>HIV Drug Resistance Report 2019. Geneva Switzerland: World Health Organisation;2019</comment>.</mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Moh</surname><given-names>R</given-names></name><name><surname>Benalycherif</surname><given-names>A</given-names></name><name><surname>Gabillard</surname><given-names>D</given-names></name><etal/></person-group>
<comment>48-Weeks efficacy of a third-line based on darunavir plus raltegravir regimen in HIV-infected adults who failed second-line protease inhibitor-based regimen in sub-Saharan. Africa, ANRS 12269 THILAO study. 9<sup>th</sup> IAS Conference on HIV science; 2017 Jul 23&#x02013;26; Paris, France</comment>.</mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Labhardt</surname><given-names>ND</given-names></name><name><surname>Ringera</surname><given-names>I</given-names></name><name><surname>Lejone</surname><given-names>TI</given-names></name><name><surname>Cheleboi</surname><given-names>M</given-names></name><name><surname>Wagner</surname><given-names>S</given-names></name><name><surname>Muhairwe</surname><given-names>J</given-names></name><name><surname>Klimkait</surname><given-names>T</given-names></name></person-group>
<article-title>When patients fail UNAIDS&#x02019; last 90 &#x02013; the &#x02018;failure cascade&#x02019; beyond 90&#x02013;90&#x02013;90 in rural Lesotho, Southern Africa: a prospective cohort study</article-title>. <source><italic>J Int AIDS Soc</italic></source>
<year>2017</year>; <volume>20</volume>:<fpage>21803</fpage>.<pub-id pub-id-type="pmid">28777506</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name><surname>Laborde-Balen</surname><given-names>G</given-names></name><name><surname>Elad</surname><given-names>O</given-names></name></person-group>
<person-group person-group-type="editor"><name><surname>Desclaux</surname><given-names>A</given-names></name><name><surname>Diarra</surname><given-names>A</given-names></name></person-group>
<article-title>&#x02018;Une impossible fin du sida? (in)visibilit&#x000e9;s globales et locales de l&#x02019;&#x000e9;chec th&#x000e9;rapeutique au Cameroun</article-title>. <publisher-name>L&#x02019;Harmattan (Collection Anthropologie et M&#x000e9;decine)</publisher-name>, <source><italic>Gu&#x000e9;rir en Afrique: promesse et transformation. Anthropologie compar&#x000e9;e</italic></source>. <publisher-loc>Paris</publisher-loc>: <year>2019</year>.</mixed-citation></ref></ref-list></back></article>